NCT04074837View on ClinicalTrials.gov

Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

56

Participants

Timeline

Start Date

August 1, 2019

Primary Completion Date

July 31, 2021

Study Completion Date

August 15, 2021

Conditions

Alzheimer Disease

Interventions

DRUG

NNI-362

NNI-362 small molecule in liquid suspension.

DRUG

Placebo

Placebo liquid suspension

Trial Locations (1)

91206

Parexel, International, Glendale

Sponsors

Lead Sponsor

Neuronascent, Inc.

All Listed Sponsors

collaborator

National Institute on Aging (NIA)

NIH

lead

Neuronascent, Inc.

INDUSTRY

NCT04074837 - Phase1a, Dose-escalation Study of NNI-362 in Healthy Aged Volunteers | Biotech Hunter | Biotech Hunter